Compare Merck & Co., Inc. (MRK) vs NetApp Inc. (NTAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs NetApp Inc. — how do they compare? Merck & Co., Inc. trades at $148 (market cap $363.98B), while NetApp Inc. trades at $184.74 (market cap $36.29B). The key difference: Merck & Co., Inc. is far larger — about 10× NetApp Inc.'s market cap, and Merck & Co., Inc. pays the higher dividend (2.3%). Which is the better fit depends on your goals.
| MRK | NTAP | |
|---|---|---|
Market Cap | $363.98B | $36.29B |
Sector | Health | Technology |
52-Week High | $156.43 | $207.08 |
52-Week Low | $77.60 | $94.11 |
Enterprise Value | $410.75B | $35.24B |
Dividend Yield | 2.3% | 1.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MRK trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and support near $147. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.22. Revenue reached $65.01B in 2025, and the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline.
Outlook remains positive with a consensus price target of $157, offering ~6% upside. Risks include high P/E of 118.77 and competitive pressures in pharma. Institutional buying and a 67.57% buy rating from analysts support a constructive view, though net income margin of 4.77% warrants monitoring.
NetApp (NTAP) trades at $189.13, up 1.91% on the day, with a bullish technical signal and strong recent earnings beats. The stock shows robust fundamentals, including a 70.63% gross margin and 19.19% net income margin, supported by record quarterly results and raised fiscal 2027 guidance. Analyst consensus is a buy with a $193.55 price target, though valuation metrics like a P/E of 26.71 indicate a premium. Recent news highlights AI-driven demand and cloud growth as key catalysts.
Outlook remains positive due to AI storage momentum and operational strength, but risks include premium valuation pressure and margin challenges. The stock offers growth potential from hybrid cloud expansion, yet investors should monitor execution against high expectations and competitive dynamics in the data infrastructure sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About NetApp Inc.
NetApp is a leading provider of enterprise data management and storage solutions. The company's three operating business units are products, software maintenance, and hardware maintenance. NetApp transitioned from a data center storage firm to a company with software data management solutions for multicloud environments. The California-headquartered company sells globally and has approximately 10,000 employees.
Read more on NTAP →
